Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial

Affiliation auteurs!!!! Error affiliation !!!!
TitreEdoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial
Type de publicationJournal Article
Year of Publication2020
AuteursVranckx P, Valgimigli M, Eckardt L, Lewalter T, Unikas R, Marin F, Schiele F, Laeis P, Reimitz P-E, Smolnik R, Zierhut W, Tijssen J, Goette A
JournalEUROPEAN HEART JOURNAL
Volume41
Pagination4497-4504
Date PublishedDEC 14
Type of ArticleArticle
ISSN0195-668X
Mots-clésAcute coronary syndromes, anticoagulation, Atrial fibrillation, Edoxaban, percutaneous coronary intervention, Stable coronary artery disease
Résumé

{Aims To compare the safety and efficacy of edoxaban combined with P2Y12 inhibition following percutaneous coronary intervention (PCI) in patients with atrial fibrillation (AF) presenting with an acute coronary syndrome (ACS) or chronic coronary syndrome (CCS). Methods and results In this pre-specified sub-analysis of the ENTRUST-AF PCI trial, participants were randomly assigned 1:1 to edoxaban- or vitamin K antagonist (VKA)-based strategy and randomization was stratified by ACS (edoxaban n = 388, VKA n = 389) vs. CCS (edoxaban n = 363
DOI10.1093/eurheartj/ehaa617